Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, November 15, 2023
[ Wed, Nov 15th 2023
] - WOPRAI
[ Wed, Nov 15th 2023
] - WOPRAI
[ Wed, Nov 15th 2023
] - WOPRAI
[ Wed, Nov 15th 2023
] - WOPRAI
Tue, November 14, 2023
[ Tue, Nov 14th 2023
] - WOPRAI
[ Tue, Nov 14th 2023
] - WOPRAI
[ Tue, Nov 14th 2023
] - WOPRAI
[ Tue, Nov 14th 2023
] - WOPRAI
[ Tue, Nov 14th 2023
] - WOPRAI
[ Tue, Nov 14th 2023
] - WOPRAI
[ Tue, Nov 14th 2023
] - WOPRAI
[ Tue, Nov 14th 2023
] - WOPRAI
[ Tue, Nov 14th 2023
] - WOPRAI
[ Tue, Nov 14th 2023
] - WOPRAI
[ Tue, Nov 14th 2023
] - WOPRAI
[ Tue, Nov 14th 2023
] - WOPRAI
[ Tue, Nov 14th 2023
] - WOPRAI
[ Tue, Nov 14th 2023
] - WOPRAI
[ Tue, Nov 14th 2023
] - WOPRAI
[ Tue, Nov 14th 2023
] - WOPRAI
[ Tue, Nov 14th 2023
] - WOPRAI
[ Tue, Nov 14th 2023
] - WOPRAI
[ Tue, Nov 14th 2023
] - WOPRAI
[ Tue, Nov 14th 2023
] - WOPRAI
[ Tue, Nov 14th 2023
] - WOPRAI
[ Tue, Nov 14th 2023
] - WOPRAI
[ Tue, Nov 14th 2023
] - WOPRAI
[ Tue, Nov 14th 2023
] - WOPRAI
[ Tue, Nov 14th 2023
] - WOPRAI
David Amsellem Downgraded (CARA) to Hold and Decreased Target to $1 on, Nov 14th, 2023
David Amsellem of Piper Sandler, Downgraded "Cara Therapeutics, Inc." (CARA) to Hold and Decreased Target from $12 to $1 on, Nov 14th, 2023.
David has made no other calls on CARA in the last 4 months.
There are 2 other peers that have a rating on CARA. Out of the 2 peers that are also analyzing CARA, 0 agree with David's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with David
- Oren Livnat of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $7 on, Thursday, October 19th, 2023
- Joseph Stringer of "Needham" Reiterated at Strong Buy and Held Target at $22 on, Tuesday, August 8th, 2023
